Alnylam Pharmaceuticals Inc

2026. g. 13. aug. 19:36 UTC

Shares of Alnylam Pharmaceuticals are higher today, marking three consecutive daily gains, despite being below the 20-day moving average and a one-month decline.

2026. g. 12. aug. 23:16 UTC

Alnylam Pharmaceuticals shares are lower in after-market hours, with no specific news identified. The broader market showed a slight rise in consumer prices.

2026. g. 11. aug. 19:46 UTC

Alnylam Pharmaceuticals shares are higher today, buoyed by broader market trends after last Friday's weak jobs report affecting Fed rate hike expectations.

2026. g. 10. aug. 22:51 UTC

Alnylam Pharmaceuticals Inc shares are higher in after-market trading, recovering from an earlier dip, though still below their 20-day moving average.

2026. g. 7. aug. 19:21 UTC

Alnylam Pharmaceuticals is trading higher, supported by a notable rise in the Biotechnology sector. The stock remains below its 20-day moving average.

2026. g. 6. aug. 22:52 UTC

Alnylam Pharmaceuticals shares are higher in after-market trading, reflecting gains since Thursday's close amid a favorable broader market backdrop.

2026. g. 5. aug. 23:01 UTC

Alnylam Pharmaceuticals shares are higher in after-market hours, though no specific news was identified to explain the movement. Recent economic data may be influencing sentiment.

2026. g. 4. aug. 23:51 UTC

Alnylam Pharmaceuticals shares are higher in after-market trading, recovering from earlier lows amid broader market optimism over oil supply agreements and easing inflation concerns.

2026. g. 3. aug. 20:02 UTC

Raymond James upgraded Alnylam Pharmaceuticals to Strong Buy with a $420 target, contributing to a notable increase in shares during Monday's session.

2026. g. 1. aug. 00:01 UTC

Alnylam Pharmaceuticals shares are lower in after-market hours, reflecting broader market declines despite a strong second-quarter revenue of $1.2 billion.

2026. g. 31. jūl. 23:16 UTC

Alnylam Pharmaceuticals reported Q2 2026 net product revenue of $1.2 billion, driven by strong AMVUTTRA uptake. Shares rose slightly in after-market trading.

2026. g. 30. jūl. 23:41 UTC

Alnylam Pharmaceuticals is rising in after-market hours, reflecting broader market gains. No specific news was identified to explain the price movement.

2026. g. 29. jūl. 19:14 UTC

Alnylam Pharmaceuticals Inc shares are lower today, influenced by the Federal Reserve's decision to maintain interest rates amid economic uncertainties and sector declines.

2026. g. 28. jūl. 20:02 UTC

Alnylam Pharmaceuticals is trading higher, benefiting from gains in the Biotechnology sector. Recent advancements in its Alzheimer's pipeline are attracting attention.

2026. g. 27. jūl. 22:41 UTC

Alnylam Pharmaceuticals shares are higher in after-market trading, continuing a trend of gains over the last three sessions despite remaining below the 20-day moving average.

2026. g. 24. jūl. 19:46 UTC

Alnylam Pharmaceuticals is trading higher, influenced by a rise in the Property & Casualty Insurance sector. Shares remain below their 20-day moving average.

2026. g. 23. jūl. 09:51 UTC

Alnylam Pharmaceuticals shares are modestly higher in pre-market hours, trading within a narrow range since Wednesday's close. The stock remains below its 20-day moving average.

2026. g. 22. jūl. 22:31 UTC

Alnylam Pharmaceuticals shares are higher in after-market trading, rebounding from earlier lows despite broader market volatility and geopolitical tensions.

2026. g. 21. jūl. 23:56 UTC

No specific news was identified for Alnylam Pharmaceuticals during after-market hours. The stock remains near unchanged since Tuesday's close.

2026. g. 20. jūl. 19:26 UTC

Alnylam Pharmaceuticals is trading higher as it initiates a Phase 2 trial of mivelsiran for Down syndrome-associated Alzheimer’s disease, signaling progress in research.